A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Part I We are a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions. We believe we have built a leading platform for dermatologic product development and commercialization. Our strategy is to focus on validated biological targets, and to use our drug development platform and deep dermatology expertise to develop and commercialize differentiated products that have the potential to address the major shortcomings of existing therapies in our targeted indications. We believe this strategy uniquely positions us to rapidly advance our goal of bridging the treatment innovation gap in dermatology, while maximizing our probability of technical success and financial resources.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 376M | 376M | 197M | - | - | 0 |
| Net Income | -16M | -16M | -140M | -262M | -311M | -206M |
| EPS | $-0.13 | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 |
| Free Cash Flow | -6.3M | -6.3M | -112M | -247M | -258M | -176M |
| ROIC | -3.7% | -5.7% | -52.9% | -90.2% | -76.5% | -55.8% |
| Gross Margin | 90.2% | 90.2% | 90.3% | - | - | - |
| Debt/Equity | 0.61 | 0.61 | 0.70 | 2.32 | 0.97 | 0.26 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -12M | -12M | -128M | -241M | -302M | -207M |
| Operating Margin | -3.3% | -3.3% | -65.3% | - | - | - |
| ROE | -8.5% | -9.3% | -88.9% | -295.6% | -148.6% | -69.3% |
| Shares Outstanding | 124M | 124M | 121M | 69M | 55M | 49M |
| Metric | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0 | 0 | N/A | N/A | 197M | 376M | 376M |
| Gross Margin | N/A | N/A | N/A | N/A | 90.3% | 90.2% | 90.2% |
| R&D | 115M | 146M | 182M | 111M | 76M | 77M | 77M |
| SG&A | 21M | 61M | 122M | 185M | 229M | 275M | 275M |
| EBIT | -137M | -207M | -302M | -241M | -128M | -12M | -12M |
| Op. Margin | N/A | N/A | N/A | N/A | -65.3% | -3.3% | -3.3% |
| Net Income | -136M | -206M | -311M | -262M | -140M | -16M | -16M |
| Net Margin | N/A | N/A | N/A | N/A | -71.3% | -4.3% | -4.3% |
| Non-Recurring | -42K | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -50.1% | -55.8% | -76.5% | -90.2% | -52.9% | -5.7% | -3.7% |
| ROE | -132.0% | -69.3% | -148.6% | -295.6% | -88.9% | -9.3% | -8.5% |
| ROA | -67.0% | -50.6% | -69.3% | -76.8% | -40.1% | -4.1% | -3.7% |
| Cash Flow | |||||||
| Op. Cash Flow | -113M | -175M | -258M | -247M | -112M | -5.6M | -5.6M |
| Free Cash Flow | -113M | -176M | -258M | -247M | -112M | -6.3M | -6.3M |
| Owner Earnings | -121M | -199M | -291M | -287M | -156M | -51M | -51M |
| CapEx | 321K | 995K | 333K | 428K | 143K | 686K | 686K |
| Maint. CapEx | 78K | 454K | 934K | 1.5M | 2.0M | 4.7M | 4.7M |
| Growth CapEx | 243K | 541K | 0 | 0 | 0 | 0 | 0 |
| D&A | 78K | 454K | 934K | 1.5M | 2.0M | 4.7M | 4.7M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 7.9M | 24M | 33M | 39M | 42M | 40M | 40M |
| Debt Repayment | 0 | 1.6M | 2.2M | 0 | 100M | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -284M | -310M | -207M | -66M | -118M | -106M | 72M |
| Cash & Equiv. | 65M | 96M | 54M | 88M | 71M | 43M | 43M |
| Long-Term Debt | 0 | 72M | 198M | 202M | 107M | 108M | 108M |
| Debt/Equity | 0.00 | 0.26 | 0.97 | 2.32 | 0.70 | 0.61 | 0.61 |
| Interest Coverage | N/A | N/A | -19.3 | -8.1 | -4.7 | -1.0 | -1.0 |
| Equity | 271M | 298M | 210M | 89M | 158M | 189M | 189M |
| Total Assets | 298M | 408M | 449M | 341M | 349M | 433M | 433M |
| Total Liabilities | 28M | 110M | 240M | 253M | 191M | 243M | 243M |
| Intangibles | 1.8M | 0 | 7.2M | 6.4M | 9.5M | 15M | 15M |
| Retained Earnings | -202M | -408M | -720M | -982M | -1.1B | -1.1B | -1.1B |
| Working Capital | 270M | 369M | 400M | 284M | 255M | 281M | 281M |
| Current Assets | 293M | 403M | 437M | 330M | 336M | 411M | 411M |
| Current Liabilities | 23M | 33M | 38M | 47M | 81M | 130M | 130M |
| Per Share Data | |||||||
| EPS | -3.80 | -4.18 | -5.66 | -3.78 | -1.16 | -0.13 | -0.13 |
| Owner EPS | -3.39 | -4.03 | -5.29 | -4.14 | -1.29 | -0.41 | -0.41 |
| Book Value | 7.58 | 6.03 | 3.81 | 1.28 | 1.30 | 1.53 | 1.53 |
| Cash Flow/Share | -3.17 | -3.54 | -4.68 | -3.56 | -0.93 | -0.05 | -0.09 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 35.7M | 49.4M | 55.0M | 69.3M | 120.7M | 124.2M | 124.2M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -185.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 3.9 | 3.5 | 3.7 | 2.6 | 11.0 | 19.0 | 15.8 |
| Price/Sales | N/A | N/A | N/A | N/A | 5.7 | 5.7 | 8.0 |
| FCF Yield | -10.9% | -17.0% | -33.4% | -108.1% | -6.5% | -0.2% | -0.2% |
| Market Cap | 1.0B | 1.0B | 774M | 229M | 1.7B | 3.6B | 3.0B |
| Avg. Price | 26.70 | 25.56 | 19.46 | 9.26 | 9.29 | 17.29 | 24.12 |
| Year-End Price | 29.25 | 20.94 | 14.06 | 3.30 | 14.30 | 28.97 | 24.12 |
Arcutis Biotherapeutics, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 90.3%.
Arcutis Biotherapeutics, Inc. (ARQT) has a 5-year average return on invested capital (ROIC) of -56.2%. This is below average and may indicate limited pricing power.
Arcutis Biotherapeutics, Inc. (ARQT) has a market capitalization of $3.0B. It is classified as a mid-cap stock.
Arcutis Biotherapeutics, Inc. (ARQT) does not currently pay a regular dividend.
Arcutis Biotherapeutics, Inc. (ARQT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Arcutis Biotherapeutics, Inc. (ARQT) reported annual revenue of $376 million in its most recent fiscal year, based on SEC EDGAR filings.
Arcutis Biotherapeutics, Inc. (ARQT) has a net profit margin of -4.3%. The company is currently unprofitable.
Arcutis Biotherapeutics, Inc. (ARQT) generated $-6 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Arcutis Biotherapeutics, Inc. (ARQT) has a debt-to-equity ratio of 0.61. This indicates moderate leverage.
Arcutis Biotherapeutics, Inc. (ARQT) reported earnings per share (EPS) of $-0.13 in its most recent fiscal year.
Arcutis Biotherapeutics, Inc. (ARQT) has a return on equity (ROE) of -9.3%. A negative ROE may indicate losses or negative equity.
Arcutis Biotherapeutics, Inc. (ARQT) has a 5-year average gross margin of 90.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for Arcutis Biotherapeutics, Inc. (ARQT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Arcutis Biotherapeutics, Inc. (ARQT) has a book value per share of $1.53, based on its most recent annual SEC filing.